查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2099678

月經治療市場 - 全球市場預測（2026-2032）

Dysmenorrhea Treatment Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，月經治療市場將成長至 158.3 億美元，複合年成長率為 9.28%。

主要市場統計數據
基準年 2025 85.1億美元
預計年份：2026年 92.4億美元
預測年份 2032 158.3億美元
複合年成長率 (%) 9.28%

月經疼痛治療執行摘要

由於月經仍然是青春期和育齡期女性最常見的婦科疾病之一，因此月經的治療在臨床和公共衛生領域的重要性日益凸顯。原發性經痛通常與前列腺素引起的子宮收縮有關，而續發性月經可能與子宮內膜異位症、子宮肌腺症、子宮肌瘤、骨盆腔炎或先天性生殖器畸形等潛在疾病有關。實證治療方案通常包括非類固醇消炎劑、荷爾蒙避孕藥、熱療、運動和生活方式調整。如果症狀嚴重、進行性或對第一線治療反應不佳，則需要評估繼發性病因。

治療月經的方法發生了變革性變化。

治療經月經的方法正從暫時緩解疼痛轉向全面的月經健康管理。傳統上，許多患者自行使用非處方藥或熱療來緩解月經，或拖延就醫。如今，人們對子宮內膜異位症和其他繼發性病因的認知不斷提高，促使患者更早接受醫療評估，更好地追蹤症狀，並建立更有系統的診療路徑。這種轉變尤其重要，因為嚴重的或持續加重的月經不應被視為“正常”，且持續存在的症狀可能提示存在需要診斷檢查和長期治療的疾病。

人工智慧對月經治療的累積影響

人工智慧 (AI) 正透過改善症狀分診、提高病患參與度和輔助臨床決策，逐步影響月經的治療。 AI 驅動的月經健康管理應用程式可以幫助使用者記錄月經週期的規律性、疼痛強度、用藥情況、出血模式以及相關症狀，例如噁心、疲勞、頭痛、腹瀉和腸道不適。如果設計得當，這些工具可以幫助及早發現需要臨床評估的症狀，例如疼痛進行性加劇、非週期性骨盆腔疼痛、月經量過多、性交疼痛、不孕症問題或疑似子宮內膜異位症的症狀。

區域性月經疼痛治療的關鍵見解

在亞太地區，中國、印度、日本、韓國和澳洲等國家對月經治療的需求日益成長，這主要歸因於青少年和育齡人口眾多、全面的月經衛生教育以及數位健康平台的日益普及。儘管該地區迫切需要便捷的疼痛管理、以學校為基礎的月經衛生意識宣傳活動以及價格合理的婦科服務，但在某些地區，文化偏見仍然阻礙著人們尋求嚴重月經的治療。旨在改善月經衛生和青少年生殖健康教育的公共衛生計畫正在不斷拓展新的服務管道，例如提供月經諮詢、安全使用止痛藥指導以及將疑似次發性月經患者轉診至醫療機構。

月經疼痛治療的主要團體分析

在東協地區，隨著人口結構年輕化、藥局普及、智慧型手機在月經週期管理中的廣泛應用以及青少年生殖健康教育意識的提高，月經的治療方式正在改變。然而，婦科醫生就診機會的差異以及個體月經健康素養的差異，使得實施基層醫療方案、學校健康計劃以及開展具有文化敏感性的患者教育變得尤為重要。在海灣合作理事會國家，對醫療基礎設施、婦女診所和數位醫療服務的投入增加，正在改善患者獲得諮詢和治療的機會。此外，注重隱私的醫療模式在月經紊亂的治療中也至關重要。

各國對月經治療的深入分析。

在美國，非處方藥、荷爾蒙避孕藥、遠端醫療諮詢以及疑似子宮內膜異位症或慢性骨盆腔疼痛的專科轉診途徑已得到廣泛應用，但醫療保健方面的不平等現象仍然影響著患者獲得診斷和治療的機會。在加拿大，基層醫療、生殖健康服務和藥物安全受到重視，尤其關注各省和偏遠社區的公平醫療服務取得。在墨西哥和巴西，擴大藥房覆蓋範圍、提高女性健康意識以及改善嚴重月經的及時婦科評估（尤其是在主要都市區以外的地區）是造成這一現象的原因之一。

為行業領導者提供的實用建議

產業領導者應優先考慮以實證醫學為基礎、以病人為中心的月經治療策略，這些策略既要緩解症狀，又要識別潛在病因。產品、服務和護理路徑的開發應與臨床指南保持一致，指南支持將非類固醇抗發炎藥物 (NSAIDs) 作為原發性經痛的一線常用療法，並在適當情況下採用荷爾蒙療法，並在疼痛劇烈、非典型、進行性或對初始治療無反應時，迅速評估繼發性病因。清晰的病患教育至關重要，包括用藥時間、禁忌症、副作用、藥物交互作用以及何時就醫。

調查方法

評估月經治療趨勢的調查方法應結合證據綜合、臨床指引回顧、監管分析以及醫療服務模式的系統性評估。可靠的資訊來源包括同儕審查的醫學文獻、公共衛生機構、婦科和青少年保健指南、藥物警戒資料、臨床試驗註冊庫以及權威醫學協會。分析應區分原發性經痛經痛和續發性月經，根據證據強度評估治療方法，並考慮與非類固醇抗發炎藥、荷爾蒙療法、熱療、運動和輔助療法相關的安全因素。

結論

治療月經正逐漸成為更廣泛的月經健康重點，它將疼痛緩解、早期診斷、數位參與和公平性獲得生殖保健服務聯繫起來。實證管理仍以合理使用非類固醇抗發炎藥物、及時進行荷爾蒙療法、非藥物支持以及及時篩檢提示次發性月經的症狀為核心。隨著月經日益被認為是影響生活品質、教育和職場的問題，醫療保健系統和行業相關人員正被敦促從對症自我護理轉向以病人為中心的結構化治療路徑。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：月經治療市場：依治療類型分類

  • 非藥物療法
  • 藥物治療

第8章：月經治療市場：依藥物類別分類

  • 荷爾蒙避孕藥
  • NSAIDs

第9章：月經治療市場：依給藥途徑分類

  • 注射藥物
  • 口服
  • 外用

第10章：月經治療市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第11章：經痛治療市場：依應用領域分類

  • 原發性經痛
  • 續發性月經

第12章：月經治療市場：依最終使用者分類

  • 診所
  • 居家照護
  • 醫院
  • 專業醫療中心
    • 健身中心
    • 婦科診所

第13章：經月經治療市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章：經月經治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：經月經治療市場：依國家分類

  • 美國
  • 中國
  • 印度
  • 英國
  • 加拿大
  • 德國
  • 澳洲
  • 巴西
  • 日本
  • 墨西哥
  • 義大利
  • 法國
  • 韓國
  • 西班牙
  • 俄羅斯

第16章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • Abbott Laboratories
  • AbbVie Inc.
  • Astellas Pharma
  • AstraZeneca
  • Bayer AG
  • Boehringer Ingelheim
  • Cipla Inc.
  • Dr. Reddy's Laboratories Ltd.
  • GlaxoSmithKline plc（GSK）
  • Haleon Plc
  • Himalaya Wellness Co.
  • Johnson & Johnson
  • Lupin
  • Novartis International AG
  • Perrigo Company plc
  • Pfizer Inc.
  • Reckitt Benckiser Group PLC.
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-742BD517DA92

The Dysmenorrhea Treatment Market is projected to grow by USD 15.83 billion at a CAGR of 9.28% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 8.51 billion
Estimated Year [2026] USD 9.24 billion
Forecast Year [2032] USD 15.83 billion
CAGR (%) 9.28%

Dysmenorrhea Treatment Executive Summary

Dysmenorrhea treatment is gaining clinical and public health importance as menstrual pain remains one of the most common gynecological complaints among adolescents and reproductive-age women. Primary dysmenorrhea is typically associated with prostaglandin-mediated uterine contractions, while secondary dysmenorrhea can be linked to underlying conditions such as endometriosis, adenomyosis, uterine fibroids, pelvic inflammatory disease, or congenital reproductive tract anomalies. Evidence-based treatment pathways commonly include nonsteroidal anti-inflammatory drugs, hormonal contraceptives, heat therapy, exercise, lifestyle modification, and evaluation for secondary causes when symptoms are severe, progressive, or poorly responsive to first-line therapy.

Demand for effective dysmenorrhea pain management is being shaped by rising menstrual health awareness, broader access to gynecological care, growing acceptance of telehealth for reproductive health consultations, and increased focus on quality of life, school attendance, workplace productivity, and patient-reported outcomes. Clinical guidelines emphasize early symptom recognition, appropriate use of analgesics before or at the onset of menses, shared decision-making around hormonal therapy, and timely referral when red-flag symptoms suggest secondary dysmenorrhea. As stigma around menstrual disorders declines, healthcare systems, payers, clinicians, and digital health platforms are prioritizing accessible, affordable, and evidence-based care models for menstrual pain relief.

Transformative Shifts in the Dysmenorrhea Treatment Landscape

The dysmenorrhea treatment landscape is shifting from episodic pain relief toward integrated menstrual health management. Historically, many patients self-managed menstrual cramps with over-the-counter analgesics, heat application, or delayed clinical consultation. Today, greater awareness of endometriosis and other secondary causes is encouraging earlier medical evaluation, improved symptom tracking, and more structured care pathways. This transition is particularly important because severe or worsening menstrual pain should not be normalized, and persistent symptoms may indicate conditions requiring diagnostic workup and long-term management.

Another transformative shift is the expansion of personalized therapy. Clinicians increasingly tailor treatment by pain severity, reproductive goals, comorbidities, contraindications to hormonal therapy, gastrointestinal, cardiovascular, or renal risk related to NSAID use, and patient preference. Digital symptom diaries, teleconsultations, and remote follow-up are improving continuity of care, especially for adolescents, students, and working women who may otherwise delay appointments. At the same time, non-pharmacological interventions such as heat therapy, physical activity, dietary counseling, relaxation strategies, and stress management are being positioned as complementary options within multimodal care. Regulatory and clinical attention to medication safety, equitable access, and menstrual health education is further reshaping how dysmenorrhea is diagnosed, treated, and monitored across care settings.

Cumulative Impact of Artificial Intelligence on Dysmenorrhea Care

Artificial intelligence is beginning to influence dysmenorrhea treatment through improved symptom triage, patient engagement, and clinical decision support. AI-enabled menstrual health applications can help users log cycle regularity, pain intensity, medication use, bleeding patterns, and associated symptoms such as nausea, fatigue, headache, diarrhea, or bowel discomfort. When designed responsibly, these tools may support earlier recognition of patterns that warrant clinical evaluation, including progressively worsening pain, non-cyclical pelvic pain, heavy menstrual bleeding, dyspareunia, infertility concerns, or symptoms suggestive of endometriosis.

In clinical environments, AI can assist in organizing patient-reported outcomes, identifying adherence gaps, and supporting risk stratification for referral. Natural language processing may help clinicians analyze patient notes and symptom histories, while predictive analytics can support population health programs focused on menstrual disorders and adolescent reproductive health. However, the cumulative impact of AI depends on data quality, privacy protection, bias mitigation, transparent algorithms, and clinical validation. AI tools should support, not replace, medical evaluation, particularly because dysmenorrhea can be primary or secondary and may overlap with complex gynecological, gastrointestinal, urological, or musculoskeletal conditions. Industry leaders that prioritize clinically validated, privacy-conscious, and inclusive AI applications are better positioned to improve dysmenorrhea care pathways and patient outcomes.

Key Regional Insights Across Dysmenorrhea Treatment

In Asia-Pacific, dysmenorrhea treatment demand is influenced by a large adolescent and reproductive-age population, increasing menstrual health education, and growing use of digital health platforms in countries such as China, India, Japan, South Korea, and Australia. The region shows strong need for accessible pain management, school-based menstrual health awareness, and affordable gynecological services, while cultural stigma in some settings continues to delay care-seeking for severe menstrual pain. Public health programs addressing menstrual hygiene and adolescent reproductive education are increasingly creating entry points for counseling on menstrual pain, safe analgesic use, and referral when symptoms suggest secondary dysmenorrhea.

North America is characterized by high availability of over-the-counter NSAIDs, broad use of hormonal contraceptives for menstrual pain management, expanding telehealth access, and growing awareness of endometriosis-related pelvic pain. Clinical practice emphasizes evidence-based therapy, shared decision-making, and evaluation for secondary dysmenorrhea when symptoms are persistent or disabling. Latin America is seeing rising attention to women's health services, pharmacy-based access to analgesics, and public health efforts that address menstrual equity, although disparities in specialist access can affect timely diagnosis of underlying gynecological conditions.

Europe benefits from structured primary care, reproductive health services, and guideline-driven approaches to dysmenorrhea treatment, with increasing focus on reducing diagnostic delay for endometriosis and improving patient-reported quality of life. In the Middle East, demand is shaped by expanding private healthcare infrastructure, rising women's health awareness, and gradual normalization of menstrual health discussions, while cultural sensitivities may still influence consultation patterns and preference for privacy-focused care. Across Africa, dysmenorrhea treatment is strongly linked to access to primary healthcare, affordability of analgesics, menstrual health literacy, and school attendance initiatives; improving education and referral pathways remains essential for distinguishing common menstrual cramps from symptoms requiring specialist evaluation.

Key Group Insights for Dysmenorrhea Treatment

Across ASEAN, dysmenorrhea treatment is shaped by a young population, expanding pharmacy access, rising smartphone-based menstrual tracking, and growing public health interest in adolescent reproductive education. However, uneven access to gynecologists and variable menstrual health literacy create opportunities for primary care protocols, school health programs, and culturally sensitive patient education. In the GCC, higher investment in healthcare infrastructure, women's health clinics, and digital care delivery is supporting improved access to consultation and treatment, while privacy-focused care models are especially relevant for menstrual disorders.

Within the European Union, harmonized regulatory standards, strong pharmacovigilance systems, and established reproductive healthcare networks support evidence-based use of analgesic and hormonal dysmenorrhea therapies. The region is also advancing policy discussions around menstrual health, workplace wellbeing, and earlier recognition of endometriosis. BRICS countries present diverse dynamics, including large patient populations, rising middle-class healthcare utilization, domestic pharmaceutical production capacity, and expanding digital health ecosystems; the main challenge remains ensuring consistent access to diagnosis and treatment across urban and rural settings.

G7 countries generally demonstrate advanced clinical infrastructure, high medicine availability, and increasing integration of digital tools into reproductive healthcare, positioning them to lead in validated patient-reported outcome systems and care standardization. NATO member countries, many of which overlap with developed healthcare systems in North America and Europe, show strong emphasis on health system resilience, supply continuity, and evidence-based care delivery. Across all groups, the common priorities are menstrual health education, safe NSAID and hormonal therapy use, improved referral for suspected secondary dysmenorrhea, privacy protection in digital reproductive health, and equitable access to patient-centered care.

Key Country Insights for Dysmenorrhea Treatment

The United States shows strong use of over-the-counter pain relievers, hormonal contraceptive options, telehealth consultations, and specialist referral pathways for suspected endometriosis or chronic pelvic pain, while care disparities continue to affect diagnosis and treatment access. Canada emphasizes primary care, reproductive health services, and medication safety, with attention to equitable access across provinces and remote communities. Mexico and Brazil are influenced by broad pharmacy access, expanding women's health awareness, and the need to improve timely gynecological evaluation for severe dysmenorrhea, particularly outside major urban centers.

In the United Kingdom, clinical pathways commonly involve primary care assessment, NSAID use, hormonal treatment options, and referral when secondary causes are suspected. Germany and France benefit from established healthcare systems, prescription oversight, and growing emphasis on endometriosis recognition. Italy and Spain show increasing public discussion of menstrual pain, quality of life, and workplace or educational impact, supporting greater demand for structured dysmenorrhea management. Russia has broad clinical capacity in urban centers, but consistency of access and patient education can vary by region.

China and India represent major priorities for dysmenorrhea treatment because of large adolescent and reproductive-age populations, rising digital health adoption, and increasing awareness of menstrual disorders. China's urban healthcare systems and digital platforms support symptom tracking and consultation, while India's public health and school-based menstrual hygiene initiatives create opportunities to connect education with pain management and referral. Japan has established gynecological care and high awareness of menstrual-related productivity concerns, encouraging use of both pharmacological and lifestyle-based management. Australia combines accessible primary care, telehealth, and public health attention to menstrual wellbeing, including rural access considerations. South Korea demonstrates strong digital engagement, advanced healthcare infrastructure, and growing interest in women's health services, supporting integrated dysmenorrhea care and earlier evaluation of persistent pelvic pain.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize evidence-based, patient-centered dysmenorrhea treatment strategies that address both symptom relief and underlying disease detection. Product, service, and care pathway development should align with clinical guidance supporting NSAIDs as common first-line therapy for primary dysmenorrhea, hormonal options when appropriate, and prompt evaluation for secondary causes when pain is severe, atypical, progressive, or unresponsive to initial treatment. Clear patient education on dosing timing, contraindications, adverse effects, drug interactions, and when to seek care is essential.

Organizations should invest in menstrual health literacy programs, adolescent-friendly care models, and privacy-conscious digital platforms that enable symptom tracking, treatment adherence support, and escalation to clinical consultation. Partnerships with schools, primary care networks, pharmacies, community health programs, and telehealth providers can improve early intervention and reduce normalization of disabling menstrual pain. Developers of AI-enabled tools should validate algorithms across diverse populations, protect sensitive reproductive health data, and ensure outputs are clinically appropriate. Leaders should also strengthen access strategies in underserved regions by supporting affordable analgesic availability, clinician training, referral pathways for endometriosis and other secondary causes, and culturally respectful communication that reduces stigma around menstrual pain.

Research Methodology

The research methodology for assessing dysmenorrhea treatment trends should combine evidence synthesis, clinical guideline review, regulatory analysis, and structured evaluation of healthcare delivery patterns. Reliable sources include peer-reviewed medical literature, public health agencies, gynecology and adolescent health guidelines, pharmacovigilance resources, clinical trial registries, and recognized medical associations. The analysis should distinguish primary dysmenorrhea from secondary dysmenorrhea, evaluate treatment modalities by evidence strength, and consider safety factors associated with NSAIDs, hormonal therapy, heat therapy, exercise, and complementary interventions.

A robust methodology also requires regional and country-level triangulation using healthcare access indicators, menstrual health policy developments, telehealth adoption patterns, medicine availability, school health initiatives, and documented barriers to care. Qualitative insights from clinicians, pharmacists, patient advocacy perspectives, and public health stakeholders can help interpret treatment behavior and unmet needs. Data validation should include cross-checking claims against authoritative clinical sources, avoiding unsupported projections, and clearly separating evidence-backed observations from emerging hypotheses. This approach supports an accurate, practical, and executive summary without relying on market sizing, market share, or forecasting.

Conclusion

Dysmenorrhea treatment is evolving into a broader menstrual health priority that connects pain relief, early diagnosis, digital engagement, and equitable access to reproductive healthcare. Evidence-based management remains centered on appropriate use of NSAIDs, hormonal therapy when suitable, non-pharmacological support, and timely investigation of symptoms that may indicate secondary dysmenorrhea. The growing recognition of menstrual pain as a quality-of-life, education, and workplace issue is encouraging healthcare systems and industry stakeholders to move beyond symptomatic self-care toward structured, patient-centered treatment pathways.

Future progress depends on improving menstrual health literacy, reducing stigma, strengthening referral networks, validating digital and AI-enabled tools, and ensuring safe, affordable access to effective therapies. Regions and countries differ in infrastructure, cultural context, and care accessibility, but the shared opportunity is clear: dysmenorrhea care can be improved through earlier recognition, personalized treatment, responsible technology use, and stronger integration between pharmacies, primary care, gynecology, and public health programs.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Dysmenorrhea Treatment Market, by Treatment Type

  • 7.1. Introduction
  • 7.2. Non Pharmacological
  • 7.3. Pharmacological

8. Dysmenorrhea Treatment Market, by Drug Class

  • 8.1. Introduction
  • 8.2. Hormonal Contraceptives
  • 8.3. Nsaids

9. Dysmenorrhea Treatment Market, by Route Of Administration

  • 9.1. Introduction
  • 9.2. Injectable
  • 9.3. Oral
  • 9.4. Topical

10. Dysmenorrhea Treatment Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Hospital Pharmacy
  • 10.3. Online Pharmacy
  • 10.4. Retail Pharmacy

11. Dysmenorrhea Treatment Market, by Application

  • 11.1. Introduction
  • 11.2. Primary Dysmenorrhea
  • 11.3. Secondary Dysmenorrhea

12. Dysmenorrhea Treatment Market, by End User

  • 12.1. Introduction
  • 12.2. Clinics
  • 12.3. Home Care
  • 12.4. Hospitals
  • 12.5. Specialty Centers
    • 12.5.1. Fitness Centers
    • 12.5.2. Gynecological Clinics

13. Dysmenorrhea Treatment Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. Dysmenorrhea Treatment Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Dysmenorrhea Treatment Market, by Country

  • 15.1. United States
  • 15.2. China
  • 15.3. India
  • 15.4. United Kingdom
  • 15.5. Canada
  • 15.6. Germany
  • 15.7. Australia
  • 15.8. Brazil
  • 15.9. Japan
  • 15.10. Mexico
  • 15.11. Italy
  • 15.12. France
  • 15.13. South Korea
  • 15.14. Spain
  • 15.15. Russia

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2025
  • 16.2. FPNV Positioning Matrix, 2025
  • 16.3. Market Concentration Analysis, 2025
    • 16.3.1. Concentration Ratio (CR)
    • 16.3.2. Herfindahl Hirschman Index (HHI)
  • 16.4. Recent Developments & Impact Analysis, 2025
  • 16.5. Product Portfolio Analysis, 2025
  • 16.6. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. Abbott Laboratories
  • 17.2. AbbVie Inc.
  • 17.3. Astellas Pharma
  • 17.4. AstraZeneca
  • 17.5. Bayer AG
  • 17.6. Boehringer Ingelheim
  • 17.7. Cipla Inc.
  • 17.8. Dr. Reddy's Laboratories Ltd.
  • 17.9. GlaxoSmithKline plc (GSK)
  • 17.10. Haleon Plc
  • 17.11. Himalaya Wellness Co.
  • 17.12. Johnson & Johnson
  • 17.13. Lupin
  • 17.14. Novartis International AG
  • 17.15. Perrigo Company plc
  • 17.16. Pfizer Inc.
  • 17.17. Reckitt Benckiser Group PLC.
  • 17.18. Sanofi S.A.
  • 17.19. Sun Pharmaceutical Industries Ltd.
  • 17.20. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL DYSMENORRHEA TREATMENT MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL DYSMENORRHEA TREATMENT MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL DYSMENORRHEA TREATMENT MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL DYSMENORRHEA TREATMENT MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL DYSMENORRHEA TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 25. GLOBAL DYSMENORRHEA TREATMENT MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL DYSMENORRHEA TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NON PHARMACOLOGICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NON PHARMACOLOGICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NON PHARMACOLOGICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PHARMACOLOGICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PHARMACOLOGICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PHARMACOLOGICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NSAIDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NSAIDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NSAIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL TOPICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL TOPICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL TOPICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ONLINE PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ONLINE PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ONLINE PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PRIMARY DYSMENORRHEA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PRIMARY DYSMENORRHEA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PRIMARY DYSMENORRHEA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL SECONDARY DYSMENORRHEA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL SECONDARY DYSMENORRHEA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL SECONDARY DYSMENORRHEA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL HOME CARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL HOME CARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL HOME CARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL SPECIALTY CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL SPECIALTY CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL SPECIALTY CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL FITNESS CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL FITNESS CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL FITNESS CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL GYNECOLOGICAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL GYNECOLOGICAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL GYNECOLOGICAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA DYSMENORRHEA TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA DYSMENORRHEA TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE DYSMENORRHEA TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 96. MIDDLE EAST DYSMENORRHEA TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. MIDDLE EAST DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. MIDDLE EAST DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 99. MIDDLE EAST DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 100. MIDDLE EAST DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 102. MIDDLE EAST DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. MIDDLE EAST DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 104. AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 107. AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 108. AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 109. AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 110. AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. ASEAN DYSMENORRHEA TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. ASEAN DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. ASEAN DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 116. ASEAN DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 117. ASEAN DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 118. ASEAN DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 119. ASEAN DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. ASEAN DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 121. GCC DYSMENORRHEA TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GCC DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. GCC DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 124. GCC DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 125. GCC DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 126. GCC DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 127. GCC DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. GCC DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPEAN UNION DYSMENORRHEA TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPEAN UNION DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPEAN UNION DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPEAN UNION DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPEAN UNION DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPEAN UNION DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPEAN UNION DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPEAN UNION DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 137. BRICS DYSMENORRHEA TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. BRICS DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. BRICS DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 140. BRICS DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 141. BRICS DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 142. BRICS DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 143. BRICS DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. BRICS DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 145. G7 DYSMENORRHEA TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. G7 DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. G7 DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 148. G7 DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 149. G7 DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 150. G7 DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 151. G7 DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. G7 DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 153. NATO DYSMENORRHEA TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 154. NATO DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. NATO DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 156. NATO DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 157. NATO DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 158. NATO DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 159. NATO DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. NATO DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 163. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 165. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 166. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 167. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 168. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 170. CHINA DYSMENORRHEA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 171. CHINA DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. CHINA DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 173. CHINA DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 174. CHINA DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 175. CHINA DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 176. CHINA DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. CHINA DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 178. INDIA DYSMENORRHEA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 179. INDIA DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. INDIA DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 181. INDIA DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 182. INDIA DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 183. INDIA DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 184. INDIA DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. INDIA DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 186. UNITED KINGDOM DYSMENORRHEA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED KINGDOM DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. UNITED KINGDOM DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 189. UNITED KINGDOM DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 190. UNITED KINGDOM DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 191. UNITED KINGDOM DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 192. UNITED KINGDOM DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. UNITED KINGDOM DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 194. CANADA DYSMENORRHEA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 195. CANADA DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. CANADA DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 197. CANADA DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 198. CANADA DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 199. CANADA DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 200. CANADA DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. CANADA DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 202. GERMANY DYSMENORRHEA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 203. GERMANY DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. GERMANY DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 205. GERMANY DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 206. GERMANY DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 207. GERMANY DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 208. GERMANY DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 209. GERMANY DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 210. AUSTRALIA DYSMENORRHEA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 211. AUSTRALIA DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. AUSTRALIA DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 213. AUSTRALIA DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 214. AUSTRALIA DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 215. AUSTRALIA DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 216. AUSTRALIA DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 217. AUSTRALIA DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 218. BRAZIL DYSMENORRHEA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 219. BRAZIL DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. BRAZIL DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 221. BRAZIL DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 222. BRAZIL DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 223. BRAZIL DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 224. BRAZIL DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 225. BRAZIL DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 226. JAPAN DYSMENORRHEA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 227. JAPAN DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. JAPAN DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 229. JAPAN DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 230. JAPAN DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 231. JAPAN DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 232. JAPAN DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 233. JAPAN DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 234. MEXICO DYSMENORRHEA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 235. MEXICO DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. MEXICO DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 237. MEXICO DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 238. MEXICO DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 239. MEXICO DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 240. MEXICO DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 241. MEXICO DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 242. ITALY DYSMENORRHEA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 243. ITALY DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. ITALY DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 245. ITALY DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 246. ITALY DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 247. ITALY DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 248. ITALY DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 249. ITALY DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 250. FRANCE DYSMENORRHEA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 251. FRANCE DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. FRANCE DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 253. FRANCE DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 254. FRANCE DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 255. FRANCE DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 256. FRANCE DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 257. FRANCE DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 258. SOUTH KOREA DYSMENORRHEA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 259. SOUTH KOREA DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. SOUTH KOREA DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 261. SOUTH KOREA DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 262. SOUTH KOREA DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 263. SOUTH KOREA DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 264. SOUTH KOREA DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 265. SOUTH KOREA DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 266. SPAIN DYSMENORRHEA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 267. SPAIN DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 268. SPAIN DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 269. SPAIN DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 270. SPAIN DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 271. SPAIN DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 272. SPAIN DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 273. SPAIN DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 274. RUSSIA DYSMENORRHEA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 275. RUSSIA DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 276. RUSSIA DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 277. RUSSIA DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 278. RUSSIA DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 279. RUSSIA DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 280. RUSSIA DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 281. RUSSIA DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 282. GLOBAL DYSMENORRHEA TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • TABLE 283. GLOBAL DYSMENORRHEA TREATMENT MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025